Monoclonal antibodies in the treatment of malignant lymphoma.
- Author:
Yi NIU
1
;
Yuan-Kai SHI
Author Information
1. Department of Medical Oncology, Cancer Hospital, CAMS and PUMC, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
therapeutic use;
Antibodies, Monoclonal, Murine-Derived;
Antibodies, Neoplasm;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Drug Delivery Systems;
methods;
Drug Design;
Humans;
Lymphoma;
therapy;
Radioimmunotherapy;
Rituximab
- From:
Acta Academiae Medicinae Sinicae
2006;28(3):435-441
- CountryChina
- Language:Chinese
-
Abstract:
Monoclonal antibodies (MoAbs) have different mechanism and adverse effects compared with cytotoxic agents. The introduction of MoAbs has improved the treatment potency to malignant lymphoma without decreasing the quality of life. However, there are many questions to be answered: What is the profound mechanism of MoAbs? How about their long-term adverse effects? What is the best medication pattern in different disease types?
